HK1215710A1 - 組蛋白去甲基化酶抑制劑 - Google Patents
組蛋白去甲基化酶抑制劑Info
- Publication number
- HK1215710A1 HK1215710A1 HK16103714.1A HK16103714A HK1215710A1 HK 1215710 A1 HK1215710 A1 HK 1215710A1 HK 16103714 A HK16103714 A HK 16103714A HK 1215710 A1 HK1215710 A1 HK 1215710A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- inhibitors
- histone demethylases
- demethylases
- histone
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261708806P | 2012-10-02 | 2012-10-02 | |
DKPA201200599 | 2012-10-02 | ||
US201361770050P | 2013-02-27 | 2013-02-27 | |
DKPA201370112 | 2013-02-27 | ||
PCT/EP2013/070457 WO2014053491A1 (en) | 2012-10-02 | 2013-10-01 | Inhibitors of histone demethylases |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1215710A1 true HK1215710A1 (zh) | 2016-09-09 |
Family
ID=52781382
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15108027.3A HK1207373A1 (zh) | 2012-10-02 | 2015-08-19 | 組蛋白去甲基的抑制劑 |
HK16103714.1A HK1215710A1 (zh) | 2012-10-02 | 2016-03-31 | 組蛋白去甲基化酶抑制劑 |
HK16111877.7A HK1223612A1 (zh) | 2012-10-02 | 2016-10-14 | 組蛋白去甲基化酶抑制劑 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15108027.3A HK1207373A1 (zh) | 2012-10-02 | 2015-08-19 | 組蛋白去甲基的抑制劑 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK16111877.7A HK1223612A1 (zh) | 2012-10-02 | 2016-10-14 | 組蛋白去甲基化酶抑制劑 |
Country Status (32)
Country | Link |
---|---|
US (3) | US20150203453A1 (zh) |
EP (3) | EP3023415B1 (zh) |
JP (2) | JP6530313B2 (zh) |
KR (1) | KR102160320B1 (zh) |
CN (2) | CN104981458B (zh) |
AP (1) | AP2015008389A0 (zh) |
BR (1) | BR112015007083A2 (zh) |
CA (2) | CA2885969C (zh) |
CL (1) | CL2015000829A1 (zh) |
CR (1) | CR20150217A (zh) |
CY (1) | CY1118695T1 (zh) |
DK (1) | DK2903968T3 (zh) |
EA (1) | EA030698B1 (zh) |
ES (2) | ES2617905T3 (zh) |
HK (3) | HK1207373A1 (zh) |
HR (1) | HRP20170358T1 (zh) |
HU (1) | HUE033380T2 (zh) |
IL (2) | IL237831A (zh) |
LT (1) | LT2903968T (zh) |
MD (1) | MD20150043A2 (zh) |
ME (1) | ME02597B (zh) |
MX (1) | MX2015003959A (zh) |
NZ (1) | NZ706635A (zh) |
PE (1) | PE20150998A1 (zh) |
PH (2) | PH12015500730A1 (zh) |
PL (2) | PL2903968T3 (zh) |
PT (2) | PT3023415T (zh) |
RS (1) | RS55764B1 (zh) |
SG (2) | SG11201502452RA (zh) |
SI (2) | SI3023415T1 (zh) |
SM (1) | SMT201700109B (zh) |
WO (1) | WO2014053491A1 (zh) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI3023415T1 (en) | 2012-10-02 | 2018-01-31 | Gilead Sciences, Inc. | Histone demethylase inhibitors |
BR112015020650A2 (pt) * | 2013-02-27 | 2017-07-18 | Epitherapeutics Aps | inibidores de histona demetilases |
EP3126345A1 (en) * | 2014-03-31 | 2017-02-08 | Gilead Sciences, Inc. | Inhibitors of histone demethylases |
EA201790154A1 (ru) | 2014-08-27 | 2017-08-31 | Джилид Сайэнс, Инк. | Соединения и способы для ингибирования гистоновых деметилаз |
EP3194387B1 (en) * | 2014-09-17 | 2019-07-31 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
US10030017B2 (en) | 2014-09-17 | 2018-07-24 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
EA201790603A1 (ru) | 2014-09-17 | 2017-10-31 | Селджен Квонтисел Рисёрч, Инк. | Ингибиторы гистондеметилазы |
WO2016068580A2 (en) | 2014-10-29 | 2016-05-06 | Dong-A Socio Holdings Co., Ltd. | Novel pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (kdms) |
DK3212789T3 (da) * | 2014-10-31 | 2020-07-27 | Massachusetts Inst Technology | Massiv parallel kombinatorisk genetik til crispr |
WO2016168349A1 (en) * | 2015-04-14 | 2016-10-20 | Gilead Sciences, Inc. | Methods of treating hepatitis b virus |
US10206930B2 (en) * | 2015-08-14 | 2019-02-19 | New York University | Methods for treating T-cell acute lymphoblastic leukemia |
WO2017099829A1 (en) | 2015-12-11 | 2017-06-15 | The General Hospital Corporation | Compositions and methods for treating drug-tolerant glioblastoma |
CN108698997A (zh) | 2015-12-28 | 2018-10-23 | 赛尔基因昆蒂赛尔研究公司 | 组蛋白脱甲基酶抑制剂 |
WO2017161012A1 (en) * | 2016-03-15 | 2017-09-21 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
WO2017198785A1 (en) * | 2016-05-18 | 2017-11-23 | Ieo - Istituto Europeo Di Oncologia S.R.L. | Oxime derivatives useful as inhibitors of histone demethylase kdm4c |
BR102017010009A2 (pt) | 2016-05-27 | 2017-12-12 | Gilead Sciences, Inc. | Compounds for the treatment of hepatitis b virus infection |
KR102202984B1 (ko) | 2016-05-27 | 2021-01-13 | 길리애드 사이언시즈, 인코포레이티드 | Ns5a, ns5b 또는 ns3 억제제를 사용하여 b형 간염 바이러스 감염을 치료하는 방법 |
JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
SI3507276T1 (sl) | 2016-09-02 | 2022-01-31 | Gilead Sciences, Inc. | Spojine modulatorja toličnih receptorjev |
US10640499B2 (en) | 2016-09-02 | 2020-05-05 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
MA46535A (fr) | 2016-10-14 | 2019-08-21 | Prec Biosciences Inc | Méganucléases modifiées spécifiques de séquences de reconnaissance dans le génome du virus de l'hépatite b |
TW202402300A (zh) | 2017-01-31 | 2024-01-16 | 美商基利科學股份有限公司 | 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型 |
JOP20180008A1 (ar) | 2017-02-02 | 2019-01-30 | Gilead Sciences Inc | مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b |
JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
CA3084582A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
WO2019123340A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
TWI796596B (zh) | 2018-02-13 | 2023-03-21 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
EP3759109B1 (en) | 2018-02-26 | 2023-08-30 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds as hbv replication inhibitors |
WO2019195181A1 (en) | 2018-04-05 | 2019-10-10 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
JP7296398B2 (ja) | 2018-04-06 | 2023-06-22 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール,ヴイ.ヴイ.アイ. | 3’3’-環状ジヌクレオチド |
TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | 2,2,─環二核苷酸 |
TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
CN108464984A (zh) * | 2018-04-09 | 2018-08-31 | 徐州维康生物科技有限公司 | 一种治疗骨肉瘤的表观遗传药物 |
CN108186643B (zh) * | 2018-04-09 | 2021-04-20 | 徐州维康生物科技有限公司 | 一种具有协同抗骨肉瘤功效的药物组合物及其应用 |
TW201945388A (zh) | 2018-04-12 | 2019-12-01 | 美商精密生物科學公司 | 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶 |
CA3093130C (en) | 2018-04-19 | 2023-10-17 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
US20190359645A1 (en) | 2018-05-03 | 2019-11-28 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide |
CN108530381B (zh) * | 2018-05-07 | 2021-09-21 | 上海科技大学 | 一种由酰胺酯制备二胺衍生物的方法 |
KR20230159715A (ko) | 2018-07-13 | 2023-11-21 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
JP2021534084A (ja) * | 2018-08-06 | 2021-12-09 | ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド | ヒストンデメチラーゼ5阻害剤およびその使用 |
CN109234313A (zh) * | 2018-09-25 | 2019-01-18 | 上海交通大学医学院附属第九人民医院 | 共转染载体及其在抗骨肉瘤药物中的应用 |
KR102635333B1 (ko) | 2018-10-24 | 2024-02-15 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
US11203591B2 (en) | 2018-10-31 | 2021-12-21 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds |
WO2020092528A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
EP3935065A1 (en) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
EP3934757B1 (en) | 2019-03-07 | 2023-02-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
US20220143061A1 (en) | 2019-03-07 | 2022-05-12 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
EP3972695A1 (en) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
CA3142513A1 (en) | 2019-06-25 | 2020-12-30 | Gilead Sciences, Inc. | Flt3l-fc fusion proteins and methods of use |
US20220257619A1 (en) | 2019-07-18 | 2022-08-18 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
WO2021034804A1 (en) | 2019-08-19 | 2021-02-25 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
CR20220129A (es) | 2019-09-30 | 2022-05-06 | Gilead Sciences Inc | Vacunas para vhb y métodos de tratamiento de vhb |
US20230031465A1 (en) | 2019-12-06 | 2023-02-02 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
CA3169348A1 (en) | 2020-03-20 | 2021-09-23 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
EP4159846A1 (en) | 2020-05-26 | 2023-04-05 | Healios K.K. | Hypoimmunogenic cells |
US20220119426A1 (en) | 2020-08-07 | 2022-04-21 | Gilead Sciences, Inc. | Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use |
CN111905102A (zh) * | 2020-09-04 | 2020-11-10 | 福建医科大学附属第一医院 | Ezh2抑制剂在治疗胶质瘤中的应用 |
TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
TW202310852A (zh) | 2021-05-13 | 2023-03-16 | 美商基利科學股份有限公司 | TLR8調節化合物及抗HBV siRNA療法之組合 |
US11976072B2 (en) | 2021-06-23 | 2024-05-07 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
CA3220923A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
US11926628B2 (en) | 2021-06-23 | 2024-03-12 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
AU2022298639A1 (en) | 2021-06-23 | 2023-12-07 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
CN114907317B (zh) * | 2022-06-01 | 2023-06-13 | 郑州大学 | 一种吡唑-乙烯基-异烟酸衍生物及其制备方法和应用 |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1524747A (en) | 1976-05-11 | 1978-09-13 | Ici Ltd | Polypeptide |
ATE28864T1 (de) | 1982-07-23 | 1987-08-15 | Ici Plc | Amide-derivate. |
GB8327256D0 (en) | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
GB8717374D0 (en) | 1987-07-22 | 1987-08-26 | Smith Kline French Lab | Pharmaceutically active compounds |
US5010099A (en) | 1989-08-11 | 1991-04-23 | Harbor Branch Oceanographic Institution, Inc. | Discodermolide compounds, compositions containing same and method of preparation and use |
US5843901A (en) | 1995-06-07 | 1998-12-01 | Advanced Research & Technology Institute | LHRH antagonist peptides |
WO1998008849A1 (de) | 1996-08-30 | 1998-03-05 | Novartis Aktiengesellschaft | Verfahren zur herstellung von epothilonen und zwischenprodukte innerhalb des verfahrens |
AU4141697A (en) | 1996-09-06 | 1998-03-26 | Obducat Ab | Method for anisotropic etching of structures in conducting materials |
US5874438A (en) | 1996-10-11 | 1999-02-23 | Bayer Aktiengesellschaft | 2,2'-bridged bis-2,4-diaminoquinazolines |
EP1367057B1 (de) | 1996-11-18 | 2008-09-17 | Gesellschaft für biotechnologische Forschung mbH (GBF) | Epothilone E und F |
US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
GB9721069D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Polymeric derivatives of camptothecin |
US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
EP1058679B1 (en) | 1998-02-25 | 2005-10-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues therof |
KR100851418B1 (ko) | 1998-11-20 | 2008-08-08 | 코산 바이오사이언시즈, 인코포레이티드 | 에포틸론 및 에포틸론 유도체의 생산을 위한 재조합 방법 및 물질 |
PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
US6620811B2 (en) | 2001-11-19 | 2003-09-16 | Hoffmann-La Roche Inc. | Isonicotin- and nicotinamide derivatives of benzothiazoles |
PT2275102E (pt) | 2002-03-13 | 2015-10-27 | Array Biopharma Inc | Derivados de benzimidazole alquilado n3 como inibidores de mek |
WO2006009734A1 (en) * | 2004-06-17 | 2006-01-26 | Wyeth | Gonadotropin releasing hormone receptor antagonists |
AU2007265368A1 (en) | 2006-06-29 | 2008-01-03 | Alantos Pharmaceuticals Holding, Inc. | Metalloprotease inhibitors |
CA2718727A1 (en) * | 2008-03-25 | 2009-10-01 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
SA109300195B1 (ar) | 2008-03-28 | 2013-04-20 | Astrazeneca Ab | تركيبة صيدلانية جديدة مضادة للسرطان |
EP2350051A4 (en) * | 2008-10-29 | 2012-05-30 | Sirtris Pharmaceuticals Inc | PYRIDINE, BICYCLIC PYRIDINE AND ITS ANALOGS AS SIRTUINE MODULATORS |
EP2461835A4 (en) | 2009-08-07 | 2013-05-15 | Wistar Inst | COMPOSITIONS WITH JARID1B INHIBITORS AND METHOD FOR THE TREATMENT OF CANCER |
UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
MX347851B (es) | 2010-03-10 | 2017-05-16 | Incyte Corp | Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1). |
EP2578569B1 (en) * | 2010-05-27 | 2015-10-28 | ASKA Pharmaceutical Co., Ltd. | Heterocyclic ring compound and h1 receptor antagonist |
WO2012007007A1 (en) * | 2010-07-15 | 2012-01-19 | Epitherapeutics Aps | Inhibitors of hdme |
US20130303545A1 (en) | 2010-09-30 | 2013-11-14 | Tamara Maes | Cyclopropylamine derivatives useful as lsd1 inhibitors |
WO2012047156A1 (en) * | 2010-10-04 | 2012-04-12 | Astrazeneca Ab | Isoxazol-3(2h)-one analogs as plasminogen inhibitors and their use in the treatment of fibrinolysis related diseases |
WO2012071469A2 (en) | 2010-11-23 | 2012-05-31 | Nevada Cancer Institute | Histone demethylase inhibitors and uses thereof for treatment o f cancer |
EP2688568B1 (en) | 2011-03-25 | 2019-06-19 | Glaxosmithkline Intellectual Property (No. 2) Limited | Cyclopropylamines as lsd1 inhibitors |
HUE050962T2 (hu) | 2011-08-15 | 2021-01-28 | Univ Utah Res Found | Hiszton demetiláz inhibitor szubsztituált (E)-N'-(1-feniletilidén)-benzohidrazid származékok |
JP6020460B2 (ja) | 2011-10-27 | 2016-11-02 | アステラス製薬株式会社 | アミノアルキル置換n−チエニルベンズアミド誘導体 |
WO2013081091A1 (ja) * | 2011-12-01 | 2013-06-06 | 国立大学法人 千葉大学 | 非特異的腎集積が低減された放射性標識ポリペプチド作製用薬剤 |
CN102585150B (zh) * | 2012-02-01 | 2013-09-04 | 嘉兴学院 | 织物涂饰用阴离子水性聚氨酯分散体的制备方法 |
WO2013123411A1 (en) | 2012-02-17 | 2013-08-22 | Board Of Regents, The University Of Texas System | Methods for diagnosing and treating cancer |
WO2013129435A1 (ja) * | 2012-02-28 | 2013-09-06 | 協和発酵キリン株式会社 | 縮環チオフェン誘導体 |
SI3023415T1 (en) | 2012-10-02 | 2018-01-31 | Gilead Sciences, Inc. | Histone demethylase inhibitors |
CA2894399A1 (en) | 2012-12-06 | 2014-06-12 | Quanticel Pharmaceuticals, Inc. | Histone demethylase inhibitors |
LT2934145T (lt) | 2012-12-19 | 2018-02-26 | Celgene Quanticel Research, Inc. | Histono demetilazės inhibitoriai |
ES2718495T3 (es) | 2012-12-21 | 2019-07-02 | Celgene Quanticel Res Inc | Inhibidores de la histona desmetilasa |
BR112015020650A2 (pt) | 2013-02-27 | 2017-07-18 | Epitherapeutics Aps | inibidores de histona demetilases |
HUE034906T2 (hu) | 2013-03-15 | 2018-03-28 | Quanticel Pharmaceuticals Inc | Hiszton-demetiláz inhibitorok |
WO2015035062A1 (en) | 2013-09-05 | 2015-03-12 | Genentech, Inc. | Antiproliferative compounds |
EP3126345A1 (en) | 2014-03-31 | 2017-02-08 | Gilead Sciences, Inc. | Inhibitors of histone demethylases |
-
2013
- 2013-10-01 SI SI201330878T patent/SI3023415T1/en unknown
- 2013-10-01 WO PCT/EP2013/070457 patent/WO2014053491A1/en active Application Filing
- 2013-10-01 CA CA2885969A patent/CA2885969C/en active Active
- 2013-10-01 SG SG11201502452RA patent/SG11201502452RA/en unknown
- 2013-10-01 RS RS20170216A patent/RS55764B1/sr unknown
- 2013-10-01 PL PL13770928T patent/PL2903968T3/pl unknown
- 2013-10-01 PT PT152006722T patent/PT3023415T/pt unknown
- 2013-10-01 DK DK13770928.3T patent/DK2903968T3/en active
- 2013-10-01 NZ NZ706635A patent/NZ706635A/en not_active IP Right Cessation
- 2013-10-01 EP EP15200672.2A patent/EP3023415B1/en active Active
- 2013-10-01 CA CA3095019A patent/CA3095019C/en active Active
- 2013-10-01 KR KR1020157011211A patent/KR102160320B1/ko active IP Right Grant
- 2013-10-01 ES ES13770928.3T patent/ES2617905T3/es active Active
- 2013-10-01 BR BR112015007083A patent/BR112015007083A2/pt active Search and Examination
- 2013-10-01 SG SG10201703682YA patent/SG10201703682YA/en unknown
- 2013-10-01 LT LTEP13770928.3T patent/LT2903968T/lt unknown
- 2013-10-01 PE PE2015000454A patent/PE20150998A1/es not_active Application Discontinuation
- 2013-10-01 EA EA201500394A patent/EA030698B1/ru not_active IP Right Cessation
- 2013-10-01 ES ES15200672.2T patent/ES2654143T3/es active Active
- 2013-10-01 CN CN201380059974.0A patent/CN104981458B/zh active Active
- 2013-10-01 ME MEP-2017-46A patent/ME02597B/me unknown
- 2013-10-01 CN CN201710513194.9A patent/CN107434803B/zh active Active
- 2013-10-01 MX MX2015003959A patent/MX2015003959A/es unknown
- 2013-10-01 US US14/381,558 patent/US20150203453A1/en active Granted
- 2013-10-01 EP EP16186022.6A patent/EP3150582A1/en not_active Withdrawn
- 2013-10-01 MD MDA20150043A patent/MD20150043A2/ro not_active Application Discontinuation
- 2013-10-01 SI SI201330511A patent/SI2903968T1/sl unknown
- 2013-10-01 JP JP2015534985A patent/JP6530313B2/ja active Active
- 2013-10-01 HU HUE13770928A patent/HUE033380T2/en unknown
- 2013-10-01 EP EP13770928.3A patent/EP2903968B1/en active Active
- 2013-10-01 AP AP2015008389A patent/AP2015008389A0/xx unknown
- 2013-10-01 PL PL15200672T patent/PL3023415T3/pl unknown
- 2013-10-01 PT PT137709283T patent/PT2903968T/pt unknown
-
2014
- 2014-08-28 US US14/472,059 patent/US10189787B2/en active Active
-
2015
- 2015-03-19 IL IL237831A patent/IL237831A/en not_active IP Right Cessation
- 2015-04-01 CL CL2015000829A patent/CL2015000829A1/es unknown
- 2015-04-01 PH PH12015500730A patent/PH12015500730A1/en unknown
- 2015-04-28 CR CR20150217A patent/CR20150217A/es unknown
- 2015-08-19 HK HK15108027.3A patent/HK1207373A1/zh unknown
-
2016
- 2016-03-31 HK HK16103714.1A patent/HK1215710A1/zh unknown
- 2016-10-14 HK HK16111877.7A patent/HK1223612A1/zh unknown
-
2017
- 2017-02-16 SM SM201700109T patent/SMT201700109B/it unknown
- 2017-02-17 US US15/436,055 patent/US10221139B2/en active Active
- 2017-03-03 HR HRP20170358TT patent/HRP20170358T1/hr unknown
- 2017-03-07 CY CY20171100297T patent/CY1118695T1/el unknown
- 2017-07-02 IL IL253259A patent/IL253259B/en not_active IP Right Cessation
- 2017-07-19 PH PH12017501306A patent/PH12017501306A1/en unknown
- 2017-11-07 JP JP2017214526A patent/JP2018016661A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL253259B (en) | Inhibitors of histone demethylases | |
HK1220460A1 (zh) | 組蛋白脫甲基酶的抑制劑 | |
HK1210611A1 (zh) | 組蛋白去甲基化酶抑制劑 | |
HUE037312T2 (hu) | Hiszton demetiláz inhibitorok | |
EP2928471A4 (en) | HISTONDEMETHYLASE INHIBITORS | |
AP4029A (en) | Inhibitors of beta-secretase | |
IL236963A0 (en) | beta-secretase inhibitors | |
HK1247920A1 (zh) | 組蛋白去甲基化酶抑制劑 | |
AU2013326554A1 (en) | Inhibitors of histone demethylases | |
PT2961736T (pt) | Inibidores de histona desmetilases |